Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Today Westlaw

Published November 16, 2026 · Updated November 17, 2026

Helus psychedelic depression drug succeeds in trial amid safety scrutiny - Westlaw Today

Read the full story at Today Westlaw

Nov 16 (Reuters) - Helus Pharma said on Monday its experimental psychedelic drug significantly improved depression symptoms in a late-stage trial.

Surfaced by 5 Google Alerts

  • Psychedelics
  • Psychedelic crime
  • Gray market psychedelics
  • Psychedelic biotech
  • Magic mushrooms